Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 11 October 2017

Indication(s)

Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Bedwetting

Essential screening, diagnosis and best strategies to manage bedwetting.

+ 3 more

Visit Bedwetting

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 3 more

Visit Chronic Obstructive Pulmonary Disease (COPD)

Related Content

More information

Category Value
Agency product number EMEA/H/C/004042
Orphan designation No
Date First Approved 19-11-2015
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Gilead Sciences International Ltd
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions